Summary
The aim of this study was to define prognostic parameters for survival in patients with malignant germ cell tumours progressing after platinum-based induction chemotherapy with or without surgery. A total of 164 progressing patients (testicular: 83%, extragonadal: 17%) were identified out of 795 patients treated with platinum-based induction chemotherapy for metastatic germ cell malignancy with or without surgery. ‘Progressive disease’ included patients who had progressed after a previous partial or complete remission as well as patients who failed primary therapy. Salvage chemotherapy consisted of ‘conventional’ platinum-based chemotherapy. Prognostic factors for survival were assessed by uni- and multivariate analyses. The resulting prognostic model was validated in an independent data set of 66 similar patients. For all 164 patients the median time from start of induction chemotherapy to progression was 10 months (range: 0–99). Thirty-eight (23%) patients relapsed after 2 years. The 5-year survival rate for all progressing patients was 30% (95% confidence interval 23–38%). In the univariate analysis the following factors most importantly predicted a poor prognosis: progression-free interval < 2 years: initial poor prognosis category (MRC criteria), < CR to induction chemotherapy, initial treatment early in the 1980s and treatment given at a ‘small’ centre. Three prognostic factors remained in the multivariate analysis: progression-free interval, response to induction treatment and the level of serum human chronic gonadotrophin (hCG) and alpha fetoprotein (AFP) at relapse. One hundred and twenty-four patients could be classified on the basis of these characteristics, Those patients with progression-free interval < 2 years, < CR to induction chemotherapy and high markers at relapse (AFP >100 kU l–1 or hCG >100 IU l–1) formed a poor prognosis group of 30 patients, none of whom survived after 3 years. Patients with at most two of these three risk factors formed a good prognosis group of 94 patients (76%) with a 47% (37–56%) 5-year survival. Thirty-eight patients from the good prognosis group with a progression-free interval of >2 years had a 2-year survival of 74% (60–88%) and 5-year survival of 61%. These prognostic groups were validated in the independent data set, in which 5-year survival rates in the good and poor risk groups were 51% and 0% respectively. One-third of patients progressing during or after platinum-based induction chemotherapy for metastatic germ cell malignancy may be cured by repeated ‘conventional’ platinum-based chemotherapy. Good prognosis parameters are: progression-free interval of > 2 years, CR to induction treatment and normal or low serum markers at relapse (hCG < 100 IU l–1 and AFP < 100 kU l–1). The results of high-dose salvage chemotherapy should be interpreted on the background of these prognostic factors.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baniel, J., Foster, R. S., Gonin, R., Messemer, J. E., Donohue, J. P. & Einhorn, L. H. (1995). Late relapse of testicular cancer. J Clin Oncol 13: 1170–1176.
Beyer, J., Kramar, A., Mandanas, R., Linkesch, W., Greinix, A., Droz, J. P., Pico, J. L., Diehl, A., Bokemeyer, C., Schmoll, H. J., Nichols, C. R., Einhorn, L. H. & Siegert, W. (1996). High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables [see comments]. J Clin Oncol 14: 2638–2645.
Broun, E. R., Nichols, C. R., Kneebone, P., Williams, S. D., Loehrer, P. J., Einhorn, L. H. & Tricot, G. J. (1992). Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117: 124–128.
Cassidy, J., Lewis, C. R., Kaye, S. B. & Kirk, D. (1992). The changing role of surgery in metastatic non-seminomatous germ cell tumour. Br J Cancer 65: 127–129.
Gerl, A., Clemm, C., Schmeller, N., Hartenstein, R., Lamerz, R. & Wilmanns, W. (1995). Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer 72: 1026–1032.
Horwich, A., A’Hearn, R., Gildersleve, J. & Dearnaley, D. P. (1993). Prognostic factor analysis of conventional dose salvage therapy of patients with metastatic non-seminomatous germ cell cancer. Proc Am Soc Clin Oncol 12: 232
Horwich, A., Sleijfer, D. T., Fossa, S. D., Kaye, S. B., Oliver, R. T., Cullen, M. H., Mead, G. M., de Wit, R., de Mulder, P. H., Dearnaley, D. P., Cook, P. A., Sylvester, R. J. & Stenning, S. P. (1997). Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15: 1844–1852.
Josefsen, D., Ous, S., Hoie, J., Stenwig, A. E. & Fossa, S. D. (1993). Salvage treatment in male patients with germ cell tumours. Br J Cancer 67: 568–572.
Lederman, G. S. & Garnick, M. B. (1986). Possible benefit of doxorubicin treatment in patients with refractory germ cell cancer. Cancer 58: 2393–2398.
Ledermann, J. A., Holden, L., Newlands, E. S., Begent, R. H., Rustin, G. J., Bagshawe, K. D. & Brampton, M. (1994). The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours. Br J Urol 74: 225–230.
Levi, J. A., Thomson, D., Harvey, V., Gill, G., Raghavan, D., Tattersall, M., Snyder, R., Burns, I., Sandeman, T., Byrne, M. & Schwarz, M. (1990). Effective salvage chemotherapy with etoposide, dactinomycin and methotrexate in refractory germ cell cancer. J Clin Oncol 8: 27–32.
Loehrer PJ, S. r., Einhorn, L. H. & Williams, S. D. (1986). VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 4: 528–536.
Margolin, B. K., Doroshow, J. H., Ahn, C., Hamasaki, V., Leong, L., Morgan, R., Raschko, J., Shibata, S., Somlo, G. & Tetef, M. (1996). Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support [see comments]. J Clin Oncol 14: 2631–2637.
Loehrer, P. J., Gonin, R., Nichols, C. R., Weathers, T. & Einhorn, L. H. (1998). Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16: 2500–2504.
McCaffrey, J. A., Mazumdar, M., Bajorin, D. F., Bosl, G. J., Vlamis, V. & Motzer, R. J. (1997). Ifosfamide-and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15: 2559–2563.
Mead, G. M., Stenning, S. P., Parkinson, M. C., Horwich, A., Fossa, S. D., Wilkinson, P. M., Kaye, S. B., Newlands, E. S. & Cook, P. A. (1992). The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party [published erratum appears in J Clin Oncol 1992 10: 867]. J Clin Oncol 10: 85–94.
Motzer, R. J., Geller, N. L., Tan, C. C., Herr, H., Morse, M., Fair, W., Sheinfeld, J., Sogani, P., Russo, P. & Bosl, G. J. (1991). Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979–1989). Cancer 67: 1305–1310.
Motzer, R. J., Bajorin, D. F., Schwartz, L. H., Hutter, H. S., Bosl, G. J., Scher, H. I., Lyn, P. & Fischer, P. (1994). Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12: 2277–2283.
Nichols, C. R., Baniel, J., Foster, R., Donohue, J. P. & Einhorn, L. H. (1994). Late relapse of germ cell tumors. Proc Am Soc Clin Oncol 13: 234
Nichols, C. R., Loehrer, P. J., Einhorn, L. H., Propert, K., Vogelzang, N. J., Crawford, E. D., Sarosdy, M. & Trump, D. (1995). Phase III study of cisplatin, etoposide and bleomycin (PVP16B) or etoposide, ifosfamide and cisplatin (VIP) in advanced stage germ cell tumors; an intergroup trial. Proc Am Soc Clin Oncol 14: 239
Siegert, W., Beyer, J., Strohscheer, I., Baurmann, H., Oettle, H., Zingsem, J., Zimmermann, R., Bokemeyer, C., Schmoll, H. J. & Huhn, D. (1994). High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 12: 1223–1231.
Williams, S. D., Birch, R., Einhorn, L. H., Irwin, L., Greco, F. A. & Loehrer, P. J. (1987). Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435–1440.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Fosså, S., Stenning, S., Gerl, A. et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80, 1392–1399 (1999). https://doi.org/10.1038/sj.bjc.6690534
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690534
Keywords
This article is cited by
-
Response to first-line treatment and histology are associated with achieving complete remission after the first salvage high-dose chemotherapy in relapsing germ cell tumor patients
Bone Marrow Transplantation (2018)
-
Salvage treatment for testicular cancer with standard- or high-dose chemotherapy: a systematic review of 59 studies
Medical Oncology (2017)
-
First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG)
Journal of Cancer Research and Clinical Oncology (2014)
-
Prognostic impact of LDH levels in patients with relapsed/refractory seminoma
Journal of Cancer Research and Clinical Oncology (2013)
-
Treatment of Relapsed/Refractory Germ Cell Tumours: An Equipoise Between Conventional and High Dose Therapy
Current Treatment Options in Oncology (2012)